Literature DB >> 16412834

Prevalence of antiphospholipid antibodies in patients with neurological symptoms.

Wolfgang Miesbach1, Andreas Gilzinger, Buket Gökpinar, Detlef Claus, Inge Scharrer.   

Abstract

OBJECTIVE AND
PURPOSE: Neurological involvement is a common feature of the antiphospholipid syndrome (APS). A variety of thrombotic and non-thrombotic manifestations may accompany the presence of antiphospholipid antibodies (aPL). PATIENTS AND METHODS: We retrospectively reviewed the prevalence of aPL in a cohort of over 350 unselected patients from a neurological clinic and studied the neurological manifestations of APS.
RESULTS: We found that within this cohort the prevalence of aPL was about 15%. Most of the patients with aPL suffered from strokes and transient ischemic attacks (TIA). One patient died from spinal infarction. Non-thrombotic manifestations also occurred in 40% of these patients, such as multiple sclerosis, chorea, seizures or cerebral malignancies. No significant correlations of the titres or different types of aPL and the type of the neurological symptoms could be found. In comparison to age and sex matched patients of the cohort where the presence of aPL could be excluded, the occurrence of non-thrombotic manifestations was significantly more frequent and varied in the group of patients with aPL. The higher incidence of stroke in the non-APS group could be explained by the significantly higher presence of other laboratory risk factors, mainly hypercholesterinemia.
CONCLUSION: This investigation indicates that aPL may play an important role in the etiology of various neurological syndromes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16412834     DOI: 10.1016/j.clineuro.2005.03.005

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  6 in total

Review 1.  Antiphospholipid syndrome: what's new in understanding antiphospholipid antibody-related stroke?

Authors:  Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2006-06       Impact factor: 4.592

Review 2.  Novel insights into associations of antibodies against cardiolipin and beta2-glycoprotein I with clinical features of antiphospholipid syndrome.

Authors:  O Shovman; B Gilburd; O Barzilai; P Langevitz; Y Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

Review 3.  Microthrombotic/microangiopathic manifestations of the antiphospholipid syndrome.

Authors:  Sonja Praprotnik; Dusan Ferluga; Alenka Vizjak; Anastazija Hvala; Tadej Avcin; Blaz Rozman
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

4.  Increased anti-phospholipid antibodies in autism spectrum disorders.

Authors:  Milo Careaga; Robin L Hansen; Irva Hertz-Piccotto; Judy Van de Water; Paul Ashwood
Journal:  Mediators Inflamm       Date:  2013-09-23       Impact factor: 4.711

Review 5.  Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy.

Authors:  Thomas Fleetwood; Roberto Cantello; Cristoforo Comi
Journal:  Front Neurol       Date:  2018-11-26       Impact factor: 4.003

Review 6.  Revisiting the molecular mechanism of neurological manifestations in antiphospholipid syndrome: beyond vascular damage.

Authors:  M Carecchio; R Cantello; C Comi
Journal:  J Immunol Res       Date:  2014-03-13       Impact factor: 4.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.